Flunixin Meglumine API: regulated veterinary formulation basics

What changes when the API is destined for a veterinary dossier.

What Flunixin Meglumine is used for

Flunixin Meglumine (CAS 42461-84-7) is a veterinary nonsteroidal anti-inflammatory drug (NSAID) that works via COX inhibition, used as the active ingredient in analgesic, antipyretic, and anti-inflammatory formulations for animal health applications. This is our sole veterinary-use product — full specification and sourcing detail is available on our Flunixin Meglumine API product page.

The salt form and what the injectable route requires

As a meglumine salt, Flunixin’s solubility profile supports injectable formulation use, which is one of its most common finished-dosage routes in veterinary practice. Confirm that the specification and assay method you are quoted are explicitly built around the meglumine salt form, and that any solubility or particle-size requirements relevant to your specific finished-dosage route are addressed directly with your supplier.

Veterinary regulatory documentation differs from human-use APIs

Veterinary API sourcing in India and for export follows its own regulatory pathway, distinct from human pharmaceutical API regulation — this affects which licensing authority and documentation framework applies. Confirm which regulatory pathway your supplier’s GMP certification and documentation actually cover before assuming human-API certification automatically extends to veterinary use. Confirm the veterinary regulatory pathway that applies to your destination market; we will share the certification and documentation we hold for your review.

Withdrawal period is a finished-product concern worth noting

Withdrawal period — the time required after treatment before an animal or its products (milk, meat) can enter the food supply — is set at the finished veterinary product level based on formulation and dosing, not determined by the API itself. It is still worth understanding as context when formulating with this compound, since it affects how your finished product will ultimately be labeled and regulated.

Documentation to request before the first PO

• Batch-specific Certificate of Analysis explicitly referencing the meglumine salt form
• Confirmed veterinary-specific GMP/regulatory documentation, distinct from human-API certification
• Solubility and particle-size data relevant to your intended finished-dosage route (e.g., injectable)
• Confirmed pharmacopoeial/veterinary monograph reference matching your filing

A short checklist before you commit

• Salt form (meglumine) explicitly confirmed on the specification and CoA
• Veterinary-specific regulatory/GMP documentation confirmed, not assumed from human-API certification
• Solubility/particle-size data confirmed for your intended finished-dosage route
• Sample CoA reviewed before committing to a bulk order

Frequently asked questions

Is veterinary API sourcing regulated the same way as human pharmaceutical APIs in India? No — veterinary API manufacturing and supply follows its own regulatory pathway, distinct from human API regulation; confirm which specific licensing and documentation framework your supplier’s certification covers.

What does “withdrawal period” mean and does it apply to the API itself? Withdrawal period is the time required after treatment before an animal or its products can enter the food supply — it is set at the finished-product level based on formulation and dosing, not determined by the raw API, though it is useful context when formulating with this compound.

Is Flunixin Meglumine available as a standard catalogue product? Yes — see our API Manufacturing page for how standard sourcing works.

Do you supply Flunixin Meglumine for export markets with veterinary-specific regulatory requirements? We can supply non-regulated export markets with export documentation prepared in-house — share your destination market and its veterinary requirements and we will confirm what we can provide.